Trial: 201804065

A Multi-center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing’s Sarcoma



Principal Investigator

Van Tine, Brian

Disease Site

Bones and Joints; Soft Tissue

Learn more about this study at: